Genmab As Stock Price History
| GMAB Stock | USD 20.51 0.55 2.76% |
Below is the normalized historical share price chart for Genmab AS extending back to June 01, 2009. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Genmab AS stands at 20.51, as last reported on the 17th of March 2025, with the highest price reaching 21.07 and the lowest price hitting 20.43 during the day.
If you're considering investing in Genmab Stock, it is important to understand the factors that can impact its price. At this point, Genmab AS is very steady. Genmab AS holds Efficiency (Sharpe) Ratio of 0.0281, which attests that the entity had a 0.0281 % return per unit of risk over the last 3 months. We have found twenty-four technical indicators for Genmab AS, which you can use to evaluate the volatility of the firm. Please check out Genmab AS's Market Risk Adjusted Performance of (0.09), standard deviation of 2.7, and Risk Adjusted Performance of (0.01) to validate if the risk estimate we provide is consistent with the expected return of 0.0774%.
At present, Genmab AS's Total Stockholder Equity is projected to increase significantly based on the last few years of reporting. The current year's Liabilities And Stockholders Equity is expected to grow to about 48.1 B, whereas Common Stock Total Equity is forecasted to decline to about 52.4 M. . At present, Genmab AS's Price Earnings Ratio is projected to slightly decrease based on the last few years of reporting. The current year's Price Earnings To Growth Ratio is expected to grow to 0.16, whereas Price To Sales Ratio is forecasted to decline to 4.26. Genmab Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 1st of June 2009 | 200 Day MA 23.89 | 50 Day MA 21.2203 | Beta 0.903 |
Genmab |
Sharpe Ratio = 0.0281
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | GMAB | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.75 actual daily | 24 76% of assets are more volatile |
Expected Return
| 0.08 actual daily | 1 99% of assets have higher returns |
Risk-Adjusted Return
| 0.03 actual daily | 2 98% of assets perform better |
Based on monthly moving average Genmab AS is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Genmab AS by adding it to a well-diversified portfolio.
Price Book 2.4352 | Enterprise Value Ebitda 7.1969 | Price Sales 0.607 | Shares Float 62.8 M | Wall Street Target Price 31 |
Genmab AS Stock Price History Chart
There are several ways to analyze Genmab Stock price data. The simplest method is using a basic Genmab candlestick price chart, which shows Genmab AS price history and the buying and selling dynamics of a specified period. Many traders also use subjective judgment to their trading calls, avoiding the need to trade based on technical analysis.
| Highest Price | March 7, 2025 | 24.14 |
| Lowest Price | February 10, 2025 | 18.69 |
Genmab AS March 17, 2025 Stock Price Synopsis
Various analyses of Genmab AS's daily price changes, such as its Balance Of Power or Price Action, are crucial when deciding whether to buy, hold, or sell Genmab Stock. It can be used to describe the percentage change in the price of Genmab AS from one trading day to the next and could be a valuable metric for traders and investors to gauge the volatility and momentum of Genmab Stock.| Genmab AS Price Daily Balance Of Power | 0.86 | |
| Genmab AS Price Rate Of Daily Change | 1.03 | |
| Genmab AS Price Action Indicator | 0.04 |
Genmab AS March 17, 2025 Stock Price Analysis
Genmab Stock Price History Data
The price series of Genmab AS for the period between Tue, Dec 17, 2024 and Mon, Mar 17, 2025 has a statistical range of 5.45 with a coefficient of variation of 6.11. Under current investment horizon, the daily prices are spread out with arithmetic mean of 21.11. The median price for the last 90 days is 21.0. The company completed 5:1 stock split on 1st of May 2018.| Open | High | Low | Close | Volume | ||
03/17/2025 | 20.96 | 21.07 | 20.43 | 20.51 | ||
| 03/14/2025 | 20.96 | 21.07 | 20.43 | 20.51 | 953,606 | |
| 03/13/2025 | 19.79 | 20.26 | 19.75 | 19.96 | 1,397,976 | |
| 03/12/2025 | 20.20 | 20.36 | 20.07 | 20.21 | 1,813,091 | |
| 03/11/2025 | 20.71 | 20.83 | 20.03 | 20.26 | 3,925,132 | |
| 03/10/2025 | 23.93 | 24.05 | 21.67 | 21.98 | 5,894,020 | |
| 03/07/2025 | 24.04 | 24.33 | 24.00 | 24.14 | 803,338 | |
| 03/06/2025 | 23.76 | 23.91 | 23.63 | 23.71 | 874,090 | |
| 03/05/2025 | 23.98 | 24.11 | 23.86 | 24.10 | 604,034 | |
| 03/04/2025 | 23.11 | 23.46 | 23.04 | 23.33 | 811,685 | |
| 03/03/2025 | 23.25 | 23.31 | 22.83 | 22.96 | 774,847 | |
| 02/28/2025 | 22.64 | 22.68 | 22.43 | 22.68 | 1,026,825 | |
| 02/27/2025 | 22.56 | 22.85 | 22.55 | 22.73 | 920,707 | |
| 02/26/2025 | 22.84 | 22.93 | 22.54 | 22.61 | 901,994 | |
| 02/25/2025 | 23.13 | 23.21 | 22.92 | 22.96 | 1,052,817 | |
| 02/24/2025 | 22.46 | 22.61 | 22.35 | 22.50 | 978,049 | |
| 02/21/2025 | 22.32 | 22.36 | 22.07 | 22.34 | 1,056,869 | |
| 02/20/2025 | 22.07 | 22.55 | 22.07 | 22.44 | 1,030,526 | |
| 02/19/2025 | 21.45 | 22.06 | 21.45 | 21.97 | 1,900,121 | |
| 02/18/2025 | 21.34 | 21.79 | 21.30 | 21.77 | 1,833,163 | |
| 02/14/2025 | 21.08 | 21.31 | 21.01 | 21.30 | 2,417,859 | |
| 02/13/2025 | 20.11 | 20.98 | 20.03 | 20.92 | 1,872,426 | |
| 02/12/2025 | 18.87 | 19.71 | 18.74 | 19.69 | 1,617,004 | |
| 02/11/2025 | 19.05 | 19.13 | 18.87 | 18.89 | 1,338,230 | |
| 02/10/2025 | 18.93 | 19.02 | 18.64 | 18.69 | 950,856 | |
| 02/07/2025 | 19.29 | 19.36 | 18.92 | 19.00 | 1,245,703 | |
| 02/06/2025 | 19.31 | 19.47 | 19.15 | 19.35 | 1,866,935 | |
| 02/05/2025 | 19.30 | 19.63 | 19.30 | 19.47 | 1,788,721 | |
| 02/04/2025 | 19.19 | 19.43 | 19.13 | 19.21 | 1,147,379 | |
| 02/03/2025 | 19.10 | 19.37 | 19.00 | 19.11 | 1,291,015 | |
| 01/31/2025 | 19.78 | 19.97 | 19.61 | 19.67 | 1,321,025 | |
| 01/30/2025 | 19.66 | 19.85 | 19.56 | 19.81 | 1,281,837 | |
| 01/29/2025 | 19.50 | 19.86 | 19.34 | 19.85 | 5,369,344 | |
| 01/28/2025 | 19.26 | 19.59 | 19.02 | 19.58 | 5,384,020 | |
| 01/27/2025 | 21.01 | 21.42 | 20.71 | 20.80 | 2,448,361 | |
| 01/24/2025 | 21.09 | 21.31 | 20.95 | 21.13 | 583,220 | |
| 01/23/2025 | 21.26 | 21.32 | 21.03 | 21.29 | 860,581 | |
| 01/22/2025 | 21.52 | 21.52 | 20.96 | 20.97 | 926,444 | |
| 01/21/2025 | 21.35 | 21.85 | 21.31 | 21.80 | 898,955 | |
| 01/17/2025 | 20.85 | 21.03 | 20.75 | 20.80 | 1,120,114 | |
| 01/16/2025 | 20.93 | 21.26 | 20.70 | 21.22 | 2,663,042 | |
| 01/15/2025 | 20.39 | 20.61 | 19.89 | 20.23 | 1,838,334 | |
| 01/14/2025 | 22.00 | 22.08 | 21.60 | 21.64 | 1,003,220 | |
| 01/13/2025 | 21.64 | 21.74 | 21.32 | 21.72 | 955,011 | |
| 01/10/2025 | 22.05 | 22.24 | 22.00 | 22.15 | 895,112 | |
| 01/08/2025 | 22.15 | 22.21 | 21.83 | 22.19 | 602,971 | |
| 01/07/2025 | 22.19 | 22.28 | 22.05 | 22.18 | 1,050,789 | |
| 01/06/2025 | 21.48 | 22.02 | 21.44 | 21.86 | 826,155 | |
| 01/03/2025 | 21.15 | 21.56 | 21.12 | 21.47 | 839,054 | |
| 01/02/2025 | 21.13 | 21.20 | 20.87 | 21.00 | 1,021,286 | |
| 12/31/2024 | 20.77 | 21.14 | 20.61 | 20.87 | 490,651 | |
| 12/30/2024 | 20.82 | 20.88 | 20.69 | 20.77 | 901,929 | |
| 12/27/2024 | 20.87 | 21.12 | 20.81 | 21.02 | 950,621 | |
| 12/26/2024 | 20.45 | 20.61 | 20.41 | 20.58 | 751,943 | |
| 12/24/2024 | 20.65 | 20.71 | 20.40 | 20.47 | 454,756 | |
| 12/23/2024 | 20.71 | 20.86 | 20.50 | 20.76 | 1,380,277 | |
| 12/20/2024 | 20.22 | 20.43 | 20.13 | 20.31 | 1,829,681 | |
| 12/19/2024 | 20.25 | 20.33 | 19.99 | 20.09 | 1,281,450 | |
| 12/18/2024 | 20.76 | 21.03 | 20.12 | 20.14 | 1,368,010 | |
| 12/17/2024 | 19.95 | 20.28 | 19.90 | 20.03 | 1,075,782 | |
| 12/16/2024 | 19.94 | 20.37 | 19.85 | 20.02 | 2,017,427 |
About Genmab AS Stock history
Genmab AS investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Genmab is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Genmab AS will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Genmab AS stock prices may prove useful in developing a viable investing in Genmab AS
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 64.6 M | 61.4 M | |
| Net Income Applicable To Common Shares | 6.4 B | 6.7 B |
Genmab AS Quarterly Net Working Capital |
|
Genmab AS Stock Technical Analysis
Genmab AS technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Did you try this?
Run Money Flow Index Now
Money Flow IndexDetermine momentum by analyzing Money Flow Index and other technical indicators |
| All Next | Launch Module |
Genmab AS Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Genmab AS's price direction in advance. Along with the technical and fundamental analysis of Genmab Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Genmab to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | (0.01) | |||
| Jensen Alpha | 0.0093 | |||
| Total Risk Alpha | 0.2723 | |||
| Treynor Ratio | (0.1) |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Complementary Tools for Genmab Stock analysis
When running Genmab AS's price analysis, check to measure Genmab AS's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genmab AS is operating at the current time. Most of Genmab AS's value examination focuses on studying past and present price action to predict the probability of Genmab AS's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genmab AS's price. Additionally, you may evaluate how the addition of Genmab AS to your portfolios can decrease your overall portfolio volatility.
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |